



1







Objective

Review:

- · Historical basis of mastitis therapy
- •Options for improving current therapies



Copyright (c) Pamela L. Ruegg, DVM, MPVM all rights reserved



7

	e	5 of 7	IMM to Tre	produ at Stre	icts in ep ag	U.S. V & Stap	Vere o h aur	develo eus	ped
			Amoxi- Mast	Polymast	DariClox	Masti- Clear	Pirsue	Spectra- mastLC	Today
Active Ingredient		Amoxicillin	Ampicillin	Cloxacillin	PenicillinG		Ceftiofur	Cephapirin	
	Label Claim	Str ag.	YES	YES	YES	YES			YES
.8		S aureus	YES	YES	YES				YES
C la		Str dys.		YES		YES		YES	
q		Strp ub.				YES			
-		Other		E. coli				CNS & E coli	
La	Label Dosing & Duration		3 tubes @ 12 h	3 tubes @ 24 h	3 tubes @ 12 h	3 tubes @ 12 h		2-8 tubes @ 24 h	2 tubes @ 12 h

Merck

Hanford

Zoetis

BI

8

Company

Merck

BI



9





Copyright (c) Pamela L. Ruegg, DVM, MPVM all rights reserved





15



14



Milk is Abnormal for 3 - 5.5 Days With or Without Treatment



16



120% ■No Treatment SpectramastLC (2 d) SpectramastLC (8 d) 1009 SpectramastLC (8 d) PolyMast (3 d) SpectramastLC (3 d) 809

Bacteriological Cure at 21 to 28 Days is Not Always Improved by Longer Treatment



Copyright (c) Pamela L. Ruegg, DVM, MPVM all rights reserved











Selective Treatment means		CLINICAL MASTITIS TREATMENT PROTOCOL		
The right cow Not chronically infected	1 - Detection	STEP 1. RETECTION OF CLINICAL CASE by million between in partice	Attens 1. Collect nils sample 2. Diskeri elementi mik 3. Send cas to hoppidal aber naking 2. Cel ken 3. Send cas to hoppidal aber naking 2. Cel ken	
Able to mount effective immune response if no antibiotics are considered	2 - Triage	STEP 2. ASSIAN SEVERITY SOME By transit respira part manager	Beven Gase Symptoms water beyond enter	
The right Pathogen Low spontaneous cure rate and acceptable therapeutic cure rate	3 - initial action	STEP 3. INITIAL ACTION By traceid braging per manager	Investige Argebrack Intervent	
Large margin of value for therapy The right Drug Appropriate spectrum of activity for	4 – justifying need for antibiotics	STEP 4. INITIAL DECISION FOR MON-SEVERE CASES To hopotal por consequent administra to response part consequent administration and become	Antibant: Trengs is not livery to be of based	
The right Duration Label treatment unless evidence-based criteria indicates extended duration will improve outcomes	5 – clinical case management	STIP 5. CINCLI CKS IMAGENIS Destructions begins per version schemeng personales version schemeng personales version schemeng personales version personales version and personales personales and personales personales personales personales personales and personales personales pere	Salar 1 Brogger smoother smoother smoother smoother smoother smoother smoother Salar 1 Salar	

Copyright (c) Pamela L. Ruegg, DVM, MPVM all rights reserved









